New study tracks how TGCT patients fare on vimseltinib in everyday life
NCT ID NCT07075471
First seen Jun 25, 2026 · Last updated Jul 28, 2026 · Updated 3 times
Summary
This observational study follows 100 people with tenosynovial giant cell tumor (TGCT) who are taking vimseltinib as part of their routine care. Researchers will collect data on how long patients stay on the drug and how it affects their quality of life. The study does not change standard treatment and simply observes real-world outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vimseltinib
- What this could lead to
- If successful, this study could provide real-world evidence on how vimseltinib affects daily life and treatment patterns for people with TGCT.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient selection and real-world variability.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TENOSYNOVIAL GIANT CELL TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Synexus Clinical Research, US INC
RECRUITINGWilmington, North Carolina, 28401, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pill shows promise for rare joint tumor in early trial
- New pill for tough tumors enters human testing
- New pill could shrink rare joint tumors without surgery
- New drug hope for rare joint tumor patients who Can't have surgery
- Leukemia drug shows promise against rare joint tumors
- New drug shows promise for rare joint tumor in early trial